Journal of Rare Disorders: Diagnosis & Therapy

contact@imedpub.com Submit a Manuscript

Rivastigimine

Rivastigmine (sold under the trademark Exelon among others) is a cholinesterase inhibitor used in the treatment of Alzheimer's and Parkinson's disease. The drug may be administered orally or by a transdermal patch; the last form reduces the increase in side effects, including nausea and vomiting. The drug is dissolved in the urine, and there seems to be fewer drug interactions. It was established in 1985 and was first used in medicine in 1997. In people with any type of dementia, rivastigmine has been shown to provide significant visual effects that can allow patients to become independent and 'sit on their own' for a long time. In particular, they appear to indicate treatment effects that are marked in patients who show a more aggressive course of disease, such as age, poor nutrition, or those who experience symptoms such as cheating or constipation.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

Awards Nomination 17+ Million Readerbase
Google Scholar citation report
Citations : 241

Journal of Rare Disorders: Diagnosis & Therapy received 241 citations as per Google Scholar report

image
Journal of Rare Disorders: Diagnosis & Therapy peer review process verified at publons
image
Abstracted/Indexed in
  • Google Scholar
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • International Committee of Medical Journal Editors (ICMJE)
  • Secret Search Engine Labs
  • Euro Pub

View More »

Open Access Journals